company background image
SRNE.Q logo

Sorrento Therapeutics OTCPK:SRNE.Q Stock Report

Last Price

US$0.11

Market Cap

US$60.4m

7D

-5.5%

1Y

-90.6%

Updated

04 Jan, 2024

Data

Company Financials

Sorrento Therapeutics, Inc.

OTCPK:SRNE.Q Stock Report

Market Cap: US$60.4m

SRNE.Q Stock Overview

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain.

SRNE.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Sorrento Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sorrento Therapeutics
Historical stock prices
Current Share PriceUS$0.11
52 Week HighUS$1.23
52 Week LowUS$0.021
Beta2.1
1 Month Change159.95%
3 Month Change13.27%
1 Year Change-90.59%
3 Year Change-98.50%
5 Year Change-95.49%
Change since IPO-99.11%

Recent News & Updates

Recent updates

Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M

Sep 29

Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial

Sep 15

Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103

Aug 31

Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC

Aug 23

Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading

Aug 17

Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?

Jul 22
Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?

Sorrento Therapeutics: The Enigma

Jul 15

Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical

Jul 07

Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues

Mar 15

Sorrento Therapeutics: Wide Oncology Pipeline, And Watch Out For COVID Updates

Oct 09

Shareholder Returns

SRNE.QUS BiotechsUS Market
7D-5.5%0.9%0.4%
1Y-90.6%10.3%28.8%

Return vs Industry: SRNE.Q underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: SRNE.Q underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is SRNE.Q's price volatile compared to industry and market?
SRNE.Q volatility
SRNE.Q Average Weekly Movement106.1%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: SRNE.Q's share price has been volatile over the past 3 months.

Volatility Over Time: SRNE.Q's weekly volatility has increased from 57% to 106% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006949Henry Jihttps://www.sorrentotherapeutics.com

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.

Sorrento Therapeutics, Inc. Fundamentals Summary

How do Sorrento Therapeutics's earnings and revenue compare to its market cap?
SRNE.Q fundamental statistics
Market capUS$60.35m
Earnings (TTM)-US$548.00m
Revenue (TTM)US$64.27m

0.9x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SRNE.Q income statement (TTM)
RevenueUS$64.27m
Cost of RevenueUS$221.74m
Gross Profit-US$157.47m
Other ExpensesUS$390.53m
Earnings-US$548.00m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.01
Gross Margin-245.01%
Net Profit Margin-852.65%
Debt/Equity Ratio-71.8%

How did SRNE.Q perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.